These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34003519)

  • 21. Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters.
    Bakker DS; de Graaf M; Nierkens S; Delemarre EM; Knol E; van Wijk F; de Bruin-Weller MS; Drylewicz J; Thijs JL
    J Allergy Clin Immunol; 2022 Jan; 149(1):125-134. PubMed ID: 34237306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166.
    Pedone MP; Dobreva M; Bastian M; Tavi J; Noonan K
    J Med Econ; 2024; 27(1):800-802. PubMed ID: 38842021
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.
    Wang B; Pan S; Yao Y; Zeng L; Zhang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1139-1149. PubMed ID: 35876397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of patient-reported global severity of atopic dermatitis in adults.
    Vakharia PP; Chopra R; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
    Allergy; 2018 Feb; 73(2):451-458. PubMed ID: 28905999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.
    Thijs JL; Strickland I; Bruijnzeel-Koomen CAFM; Nierkens S; Giovannone B; Csomor E; Sellman BR; Mustelin T; Sleeman MA; de Bruin-Weller MS; Herath A; Drylewicz J; May RD; Hijnen D
    J Allergy Clin Immunol; 2017 Sep; 140(3):730-737. PubMed ID: 28412391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
    Simpson EL; Lacour JP; Spelman L; Galimberti R; Eichenfield LF; Bissonnette R; King BA; Thyssen JP; Silverberg JI; Bieber T; Kabashima K; Tsunemi Y; Costanzo A; Guttman-Yassky E; Beck LA; Janes JM; DeLozier AM; Gamalo M; Brinker DR; Cardillo T; Nunes FP; Paller AS; Wollenberg A; Reich K
    Br J Dermatol; 2020 Aug; 183(2):242-255. PubMed ID: 31995838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
    Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
    Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological Therapies for Atopic Dermatitis: A Systematic Review.
    Zhou S; Qi F; Gong Y; Zhang J; Zhu B
    Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report.
    Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2021 Sep; 48(9):e472-e473. PubMed ID: 34151450
    [No Abstract]   [Full Text] [Related]  

  • 31. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities.
    He H; Del Duca E; Diaz A; Kim HJ; Gay-Mimbrera J; Zhang N; Wu J; Beaziz J; Estrada Y; Krueger JG; Pavel AB; Ruano J; Guttman-Yassky E
    J Allergy Clin Immunol; 2021 Apr; 147(4):1369-1380. PubMed ID: 33011244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
    Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis.
    Lee HH; Patel KR; Rastogi S; Singam V; Vakharia PP; Chopra R; Silverberg JI
    J Am Acad Dermatol; 2020 Jan; 82(1):62-71. PubMed ID: 31202874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis.
    Raimondo A; Guglielmi G; Marino C; Ligrone L; Lembo S
    Clin Exp Dermatol; 2022 Mar; 47(3):592-593. PubMed ID: 34655234
    [No Abstract]   [Full Text] [Related]  

  • 35. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.
    Brunner PM; Suárez-Fariñas M; He H; Malik K; Wen HC; Gonzalez J; Chan TC; Estrada Y; Zheng X; Khattri S; Dattola A; Krueger JG; Guttman-Yassky E
    Sci Rep; 2017 Aug; 7(1):8707. PubMed ID: 28821884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atopic dermatitis and multilocular alopecia areata simultaneously treated with baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):T200-T201. PubMed ID: 37952837
    [No Abstract]   [Full Text] [Related]  

  • 37. Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib.
    Pestana M; Brito Caldeira M; Duarte B
    Actas Dermosifiliogr; 2024 Feb; 115(2):200-201. PubMed ID: 36842474
    [No Abstract]   [Full Text] [Related]  

  • 38. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
    Yosipovitch G; Papp K; Forman S; Han G; Waibel J; Rueda MJ; Sun L; Chen YF; Goldblum O; Pierce E; Silverberg JI
    Br J Dermatol; 2022 Jun; 186(6):1047-1049. PubMed ID: 35041213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting.
    d'Alessandro M; Perillo F; Metella Refini R; Bergantini L; Bellisai F; Selvi E; Cameli P; Manganelli S; Conticini E; Cantarini L; Sestini P; Frediani B; Bargagli E
    Int Immunopharmacol; 2020 Sep; 86():106748. PubMed ID: 32645631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis.
    Uchiyama A; Fujiwara C; Inoue Y; Ishikawa M; Motegi SI
    J Dermatol Sci; 2022 Jun; 106(3):189-192. PubMed ID: 35459598
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.